Oral pill aims to keep weight off after initial loss
NCT ID NCT07804797
First seen Sep 04, 2026 · Last updated Sep 04, 2026
Summary
This phase 2 trial tests whether MWN109 tablets can help non-diabetic adults with overweight or obesity maintain weight loss over 24 weeks. Participants who already lost at least 5% of their body weight in a prior study will take the tablet either once daily or once weekly. Researchers will measure changes in body weight and waist circumference to see if the drug helps keep the weight off.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- MWN109 tablets, an oral medication taken once daily or once weekly
- What this could lead to
- If successful, MWN109 tablets could offer a convenient oral option to help people sustain weight loss after initial treatment, potentially reducing obesity-related health risks.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not hold in larger groups. The medication may cause side effects or fail to maintain weight loss better than no treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
71 people
The number who actually took part.
- Started
-
Mar 2026
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Participate in the multi-center, randomized, double-blind, placebo-controlled Phase II clinical trial (MWN109-II-WL) to evaluate the efficacy and safety of MWN109 injection in adult non-diabetic overweight or obese participants in China; complete the EOT visit and safety follow-up of the participants. 2. Participants whose weight decreased by ≥5% compared to baseline at the EOT visit of the MWN109-II-WL study. 3. Participants with a BMI \> 18.5 kg/m² at the time of the safety follow-up in the MWN109-II-WL study and at the time of randomization at Visit 2 (V2) of this study, and who were evaluated by the investigator as suitable for participating in this study. 4. Agree not to use other weight-loss drugs or treatments during the study period. 5. From the time of signing the informed consent until 3 months after the last dose of the investigational drug, the participant must have no intention of becoming pregnant and must voluntarily use effective contraceptive measures to prevent pregnancy (or ensure their partner does). There must be no plans for sperm or egg donation. Participants of childbearing potential must not be breastfeeding, and the pregnancy test result prior to randomization must be negative. Exclusion Criteria: 1. Previously diagnosed with type 1, type 2, or any other type of diabetes (excluding gestational diabetes). 2. At the EOT visit of the MWN109-II-WL study, the fasting plasma glucose in the central laboratory was ≥ 7.0 mmol/L, or the HbA1c was ≥ 6.5%. 3. At the screening stage, the PHQ-9 questionnaire score was ≥ 15; or at the screening stage, there was a suicidal tendency or suicidal behavior, or the subject was judged to have a suicidal risk. 4. Plans to participate in another clinical study of a trial drug or device before completing all the scheduled assessments in this clinical study, or to take drugs or non-drug treatments that affect weight (excluding diet and exercise control).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Overweight , obesity are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mushrooms and a repurposed antidepressant: a new recipe for weight loss?
- Can a damaged kidney change how a drug works?
- Can a new injection help tackle obesity? a trial puts MWN105 to the test
- Can a weekly shot help shed pounds in obesity?
- Can when you eat change how a diabetes drug works?
- Can a new injection tackle obesity, diabetes, and liver disease?